Skip to main content

PhaseBio Pharmaceuticals Inc

PHASDelisted Dec 21, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001169245

PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.

Q1 2022 vs. Q4 2021

How the institutions holding PhaseBio Pharmaceuticals Inc changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of PHAS: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders5257+5
Shares28.2M29.4M+1.26M (+4.5%)
Value$73.5M$38.8M−$34.7M (−47.2%)

New holders (11)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to PHAS in Q1 2022
InstitutionSharesValue% of portfolio
MAI Capital Management1,418,279$1.87M0.03%
Towercrest Capital Management1,051,940$1.39M0.27%
Vericrest Private Wealth1,051,940$1.39M1.44%
Renaissance Technologies LLC89,300$118.0K0.00%
Virtu Financial LLC31,305$41.0K0.00%
United Bank26,900$36.0K0.00%
Schonfeld Strategic Advisors LLC25,500$34.0K0.00%
Two Sigma Securities, LLC21,479$28.0K0.00%
Cubist Systematic Strategies, LLC20,143$27.0K0.00%
Curi Capital4,070$5.00K0.00%
Capital Advisory Group Advisory Services, LLC2,800$4.00K0.00%

Sold out (6)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of PHAS in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
ExodusPoint Capital Management, LP394,211$1.03M
Susquehanna International Group, LLP273,100$713.0K
Citadel Advisors LLC37,452$98.0K
XTX Topco Ltd15,574$41.0K
D. E. Shaw & Co., Inc.11,796$31.0K
Sargent Investment Group, LLC11,675$30.0K